Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
George D DemetriFilippo De BraudAlexander E DrilonSalvatore SienaManish R PatelByoung Chul ChoStephen V LiuMyung-Ju AhnChao-Hua ChiuJessica J LinKoichi GotoJeeyun LeeLyudmila BazhenovaThomas JohnMarwan FakihSant P ChawlaRafal DziadziuszkoTakashi SetoSebastian HeinzmannBethany PitcherDavid ChenTimothy R WilsonChristian RolfoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with NTRK fusion-positive solid tumors.
Keyphrases